Kyle R. Cron

1.0k total citations · 1 hit paper
10 papers, 794 citations indexed

About

Kyle R. Cron is a scholar working on Oncology, Molecular Biology and Biotechnology. According to data from OpenAlex, Kyle R. Cron has authored 10 papers receiving a total of 794 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Molecular Biology and 3 papers in Biotechnology. Recurrent topics in Kyle R. Cron's work include Cancer Research and Treatments (3 papers), DNA Repair Mechanisms (3 papers) and Ubiquitin and proteasome pathways (3 papers). Kyle R. Cron is often cited by papers focused on Cancer Research and Treatments (3 papers), DNA Repair Mechanisms (3 papers) and Ubiquitin and proteasome pathways (3 papers). Kyle R. Cron collaborates with scholars based in United States and China. Kyle R. Cron's co-authors include Xiaojuan Liu, Justin Kline, Liufu Deng, William A. Frazier, Yang Pu, Hua Peng, Hairong Xu, Yang‐Xin Fu, Meng Xu and Abigail L. Sedlacek and has published in prestigious journals such as Nature Medicine, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Kyle R. Cron

8 papers receiving 782 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CD47 blockade triggers T cell–mediated destruction of immunogenic tumors

2015 611 citations Xiaojuan Liu, Yang Pu et al. Nature Medicine profile →

Peers

Countries citing papers authored by Kyle R. Cron

Since Specialization

Citations

This map shows the geographic impact of Kyle R. Cron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyle R. Cron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyle R. Cron more than expected).

Fields of papers citing papers by Kyle R. Cron

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kyle R. Cron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyle R. Cron. The network helps show where Kyle R. Cron may publish in the future.

Co-authorship network of co-authors of Kyle R. Cron

This figure shows the co-authorship network connecting the top 25 collaborators of Kyle R. Cron. A scholar is included among the top collaborators of Kyle R. Cron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kyle R. Cron. Kyle R. Cron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Title	Journal	Authors	Indexed citations
1	ACTM-838, a novel systemically delivered bacterial immunotherapy that enriches in solid tumors and delivers IL-15/IL-15Rα and STING payloads to engage innate and adaptive immunity in the TME and enable a durable anti-tumor immune response	Oncotarget	Kyle R. Cron, Ping Fang et al.	0
2	Abstract 576: ACTM-838, a novel immunotherapy that enriches in solid tumors after IV dosing and comprehensively reverses the immunosuppressive TME to promote durable anti-tumor immunity	Cancer Research	Ping Fang, Kyle R. Cron et al.	1
3	642 Decreased host PKC-delta is associated with the T cell-inflamed tumor microenvironment and improves anti-tumor immunity	SHILAP Revista de lepidopterología	Kyle R. Cron, Ayelet Sivan et al.	1
4	Treatment with tocilizumab does not inhibit induction of anti-COVID-19 antibodies in patients with severe SARS-CoV-2 infection	Clinical Cancer Research	Alexandra Cabanov, Blake Flood et al.	0
5	Abstract S04-02: Treatment with tocilizumab does not inhibit induction of anti-COVID-19 antibodies in patients with severe SARS-CoV-2 infection	Clinical Cancer Research	Alexandra Cabanov, Blake Flood et al.	1
6	USP9X inhibition promotes radiation-induced apoptosis in non-small cell lung cancer cells expressing mid-to-high MCL1	Cancer Biology & Therapy	Deepa Kushwaha, Colin O’Leary et al.	31
7	CD47 blockade triggers T cell–mediated destruction of immunogenic tumors breakdown →	Nature Medicine	Xiaojuan Liu, Yang Pu et al.	611
8	IFN-γ Mediates the Antitumor Effects of Radiation Therapy in a Murine Colon Tumor	American Journal Of Pathology	Scott A. Gerber, Abigail L. Sedlacek et al.	101
9	Proteasome Inhibitors Block DNA Repair and Radiosensitize Non-Small Cell Lung Cancer	PLoS ONE	Kyle R. Cron, Kaya Zhu et al.	46
10	Proteasome Inhibitors Block DNA Repair and Radiosensitize Non-Small Cell Lung Cancer	International Journal of Radiation OncologyBiologyPhysics	David Kozono, Kyle R. Cron et al.	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact